Search

The TINCR (Terminal differentiation-Induced Non-Coding RNA) gene is selectively expressed in epithelium tissues and is involved in the control of human epidermal differentiation and wound healing. Despite its initial report as a long non-coding RNA, the TINCR locus codes for a highly conserved ubiquitin-like microprotein associated with keratinocyte differentiation. Here we report the identification of TINCR as a tumor suppressor in squamous cell carcinoma (SCC). TINCR is upregulated by UV-induced DNA damage in a TP53-dependent manner in human keratinocytes. Decreased TINCR protein expression is prevalently found in skin and head and neck squamous cell tumors and TINCR expression suppresses the growth of SCC cells in vitro and in vivo. Consistently, Tincr knockout mice show accelerated tumor development following UVB skin carcinogenesis and increased penetrance of invasive SCCs. Finally, genetic analyses identify loss-of-function mutations and deletions encompassing the TINCR gene in SCC clinical samples supporting a tumor suppressor role in human cancer. Altogether, these results demonstrate a role for TINCR as protein coding tumor suppressor gene recurrently lost in squamous cell carcinomas.

A primary precursor of jasmonates, 12- oxo -phytodienoic acid (OPDA), is an autonomous hormone signal that activates and fine-tunes plant defense responses, as well as growth and development. However, the architecture of its signaling circuits remains largely elusive. Here we describe that OPDA signaling drives photosynthetic reductant powers toward sulfur assimilation in the chloroplasts, incorporating sulfide into cysteine. Under stressed states, OPDA—accumulated in the chloroplasts—binds and promotes cyclophilin 20-3, an OPDA receptor, to transfer electrons from thioredoxin F2, an electron carrier in the photosynthesis reaction, to serine acetyltransferase 1 (SAT1). The charge carrier (H+, e−) then splits dimeric SAT1 trimers in half to signal the recruitment of dimeric O -acetylserine(thiol)lyase B, forming a hetero-oligomeric cysteine synthase complex (CSC). CSC formation and its metabolic products (especially glutathione) then coordinate redox-resolved retrograde signaling from the chloroplasts to the nucleus in adjusting expression of OPDA-responsive genes such as GLUTAREDOXIN 480 and CYTOCHROME P450 , and triggering defense responses against various ecological constraints such as salinity and excess oxidants, as well as mechanical wounding. We thus conclude that OPDA signaling regulates a unique metabolic switch in channeling light input into outputs that fuel/shape a multitude of physiological processes, optimizing plant growth fitness and survival capacity under a range of environmental stress cues. [ABSTRACT FROM AUTHOR]

Previous attempts to obtain the structure of mammalian tetrameric PFK1 used native protein or recombinant protein generated in yeast or bacteria. A limitation of using native PFK1 is that most [...], Phosphofructokinase-1 (PFK1), the 'gatekeeper' of glycolysis, catalyses the committed step of the glycolytic pathway by converting fructose-6-phosphate to fructose-1,6-bisphosphate. Allosteric activation and inhibition of PFK1 by over ten metabolites and in response to hormonal signalling fine-tune glycolytic flux to meet energy requirements (1). Mutations inhibiting PFK1 activity cause glycogen storage disease type VII, also known as Tarui disease (2), and mice deficient in muscle PFK1 have decreased fat stores (3). Additionally, PFK1 is proposed to have important roles in metabolic reprogramming in cancer (4,5). Despite its critical role in glucose flux, the biologically relevant crystal structure of the mammalian PFK1 tetramer has not been determined. Here we report the first structures of the mammalian PFK1 tetramer, for the human platelet isoform (PFKP), in complex with [ATP-Mg.sup.2+] and ADP at 3.1 and 3.4 Å, respectively. The structures reveal substantial conformational changes in the enzyme upon nucleotide hydrolysis as well as a unique tetramer interface. Mutations of residues in this interface can affect tetramer formation, enzyme catalysis and regulation, indicating the functional importance of the tetramer. With altered glycolytic flux being a hallmark of cancers (6), these new structures allow a molecular understanding of the functional consequences of somatic PFK1 mutations identified in human cancers. We characterize three of these mutations and show they have distinct effects on allosteric regulation of PFKP activity and lactate production. The PFKP structural blueprint for somatic mutations as well as the catalytic site can guide therapeutic targeting of PFK1 activity to control dysregulated glycolysis in disease.

TYW1 is a metalloenzyme involved in the modifications of guanosine 37 of Phe-tRNA of Eukaryota and Archaea. It catalyzes the second step of Wybutosine biosynthesis, which consists of the formation of the tricyclic compound imG-14 from m1G using pyruvate and SAM (S-adenosyl-methionine) as co-substrates. Two [4Fe–4S] clusters are needed in the catalytic process. One effects the reductive binding of SAM, which initiates the radical reaction that inserts a C–C moiety into m1G. The other [4Fe–4S] cluster binds the pyruvate molecule that provides the C–C motif. Using a combination of EPR and Mössbauer spectroscopy, we have been able to probe the binding of both cofactors to the FeS clusters. The results highlight an interaction between pyruvate and SAM, indicating that they bind in close vicinity inside the catalytic pocket. They also indicate a chelating binding mode of pyruvate to the accessible Fe site of the corresponding FeS cluster. This binding mode has been used to construct a docking model of holoTYW1 with pyruvate and SAM, which is consistent with the spectroscopic findings. [ABSTRACT FROM AUTHOR]

Variants of SARS-CoV-2 have continued to emerge across the world and cause hundreds of deaths each week. Due to the limited efficacy of vaccines against SARS-CoV-2 and resistance to current therapies, additional anti-viral therapeutics with pan-coronavirus activity are of high interest. Here, we screen 2.8 billion compounds from a DNA-encoded chemical library and identify small molecules that are non-covalent inhibitors targeting the conserved 3CL protease of SARS-CoV-2 and other coronaviruses. We perform structure-based optimization, leading to the creation of a series of potent, non-covalent SARS-CoV-2 3CL protease inhibitors, for coronavirus infections. To characterize their binding mechanism to the 3CL protease, we determine 16 co-crystal structures and find that optimized inhibitors specifically interact with both protomers of the native homodimer of 3CL protease. Since 3CL protease is catalytically competent only in the dimeric state, these data provide insight into the design of drug-like inhibitors targeting the native homodimer state. With a binding mode different from the covalent 3CL inhibitor nirmatrelvir, the protease inhibitor in the COVID drug Paxlovid, these compounds may overcome resistance reported for nirmatrelvir and complement its clinical utility., Competing Interests: Competing interests: S.I., H.L., A.Z., F.F., B.R.S., A.C., and D.D.H. are inventors on a patent application submitted based on this work. B.R.S. is an inventor on additional patents and patent applications related to small molecule therapeutics, and co-founded and serves as a consultant to Exarta Therapeutics, and ProJenX Inc., serves as a consultant to Weatherwax Biotechnologies and Akin Gump Strauss Hauer & Feld LLP, and holds equity in Sonata Therapeutics. S.I. and D.D.H. have sponsored research agreements with Enanta Pharmaceuticals, Shionogi & Co., Ltd., and Regeneron Pharmaceuticals. D.D.H. is a co-founder of TaiMed Biologics and RenBio, consultant to WuXi Biologics, Brii Biosciences, Apexigen, and Veru Inc., and board director for Vicarious Surgical. The remaining authors declare no competing interests., (© 2024. The Author(s).)

Importance: Cyanide is an inhibitor of heme-copper oxidases, which are required for aerobic respiration in all eukaryotes and many prokaryotes. This fast-acting poison can arise from diverse sources, but mechanisms by which bacteria sense it are poorly understood. We investigated the regulatory response to cyanide in the pathogenic bacterium Pseudomonas aeruginosa , which produces cyanide as a virulence factor. Although P. aeruginosa has the capacity to produce a cyanide-resistant oxidase, it relies primarily on heme-copper oxidases and even makes additional heme-copper oxidase proteins specifically under cyanide-producing conditions. We found that the protein MpaR controls expression of cyanide-inducible genes in P. aeruginosa and elucidated the molecular details of this regulation. MpaR contains a DNA-binding domain and a domain predicted to bind pyridoxal phosphate (vitamin B6), a compound that is known to react spontaneously with cyanide. These observations provide insight into the understudied phenomenon of cyanide-dependent regulation of gene expression in bacteria., Competing Interests: The authors declare no conflict of interest.

We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.